3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
8
Polycystic Ovary Syndrome
7
Carcinoma, Non-Small-Cell Lung
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Lung Neoplasms
4
Metabolic Syndrome
3
Insulin Resistance
3
Adenocarcinoma of Lung
3
Lymphoma, Large B-Cell, Diffuse
2
Glioblastoma
2
Carcinoma, Renal Cell
2
pCR Rate
1
Weight Gain
1
Thyroid Diseases
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Neoplasms
1
Neoplasm Metastasis
1
Mouth Neoplasms
1
Motor Activity
1
Melanoma
1
Lymphoma
1
Leukoplakia
1
Leukemia, Myelomonocytic, Acute
1
Interventions
Filgrastim
8
Cyclophosphamide
8
Cyclosporine
7
fludarabine phosphate
6
Antilymphocyte Serum
6
Rituximab
5
Radiotherapy
5
Peripheral Blood Stem Cell Transplantation
5
Mycophenolic Acid
5
Methotrexate
5
Cord Blood Stem Cell Transplantation
5
Etoposide
4
Busulfan
4
Whole-Body Irradiation
3
Methylprednisolone
3
Melphalan
3
Vincristine
2
Tacrolimus
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Doxorubicin
2
Cytarabine
2
Carboplatin
2
Amplified Fragment Length Polymorphism Analysis
2
venetoclax
1
pegfilgrastim
1
obatoclax
1
ibritumomab tiuxetan
1
fludarabine
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Dendritic Cell Sarcoma, Interdigitating
×
Metformin
×
Clear all
NCT02531308
2022-09-28
DLBCL
Rush University Medical Center
Phase 2
Terminated
5 enrolled
5 charts